February 2018 Volume 4, Issue 3

February 2018

Volume 4, Issue 3

This issue features a conversation with National Cancer Institute Director Norman “Ned” Sharpless, MD, a look at the prevalence and controversial nature of academic-industry partnerships, and more.

Table of Contents

February 2018 Issue

The Good Steward of Science

Thursday, February 1st, 2018
I have participated in a number of clinical trials and database projects with pharmaceutical companies and, as a result, have been an author on...

February 2018 Issue

Amelia Langston Named Medical Director of Winship Cancer Network, Jordan Scott Orange Receives Edith...

Thursday, February 1st, 2018
Amelia Langston Named Medical Director of Winship Cancer Network Amelia (Amy) Langston, MD, joined the Winship Cancer Institute of Emory University as medical director of...

Alexis Thompson Begins Term as 2018 ASH President, Course on Biosimilars Available, and more

Thursday, February 1st, 2018
Alexis A. Thompson, MD, MPH, Begins Term as 2018 ASH President Alexis A. Thompson, MD, MPH, a world-renowned expert in sickle cell disease and thalassemia,...

February 2018 Issue

Dr. Platzbecker with his daughters on a vacation in France.

Pulling Back the Curtain: Uwe Platzbecker, MD

Thursday, February 1st, 2018
In this edition, Uwe Platzbecker, MD, shares his long and winding path to hematology – from a stint in the East German army, to...

Big Questions, Tough Answers

Thursday, February 1st, 2018
On October 17, 2017, Norman “Ned” Sharpless, MD, was sworn in as the 15th director of the National Cancer Institute (NCI), succeeding Harold E....

Conflict Resolution: Research Under the Influence

Thursday, February 1st, 2018
In an ideal world, medical advances would result from an altruistic pairing of outstanding translational science with well-designed and efficient clinical trials, and the...

February 2018 Issue

How I Treat In Brief: Post-Transplant, Relapsed Classical Hodgkin Lymphoma

Thursday, February 1st, 2018
This month, Lapo Alinari, MD, PhD, and Kristie A. Blum, MD, discuss treatment options for patients with classical Hodgkin lymphoma (cHL) whose disease has...

How would you manage VTE risk in a transgender patient who needs hormone replacement...

Thursday, February 1st, 2018
This month, Kenneth A. Bauer, MD, discusses venous thromboembolism (VTE) risk in a transgender patient who needs hormone replacement therapy. And don't forget to check...

February 2018 Issue

Momelotinib Trial in Myelofibrosis Fails to Meet Primary Endpoint

Thursday, February 1st, 2018
The Janus kinase (JAK) inhibitor ruxolitinib is the only treatment approved by the U.S. Food and Drug Administration for patients with myelofibrosis (MF), and...

Can R-CHOP Plus Bortezomib Improve Outcomes in Patients With Non-GCB DLBCL?

Thursday, February 1st, 2018
In patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), adding the proteasome inhibitor bortezomib to standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) did...

Adding Pharmacomechanical Thrombolysis to Anticoagulation Does Not Improve Outcomes in Proximal DVT

Thursday, February 1st, 2018
The objective of pharmacomechanical thrombolysis, or the delivery of a fibrinolytic drug into the thrombus with concomitant thrombus aspiration, is to diminish the thrombus...

Is Oral Edoxaban an Alternative to Standard Anticoagulation in Cancer-Associated VTE?

Thursday, February 1st, 2018
Low-molecular-weight heparin is the standard, guideline-recommended anticoagulation therapy for patients with cancer and venous thromboembolism (VTE), but the daily subcutaneous injections can be burdensome....

Understanding Bone Disease and Fractures in Patients With MGUS

Thursday, February 1st, 2018
Patients with monoclonal gammopathy of undetermined significance (MGUS; a precursor to multiple myeloma and other lymphoproliferative disorders) are known to be at an...
WIB_icon

Can AMT-060 Gene Therapy FIX Hemophilia B?

Thursday, February 1st, 2018
After a single infusion of AMT-060 (an adeno-associated virus-5 vector carrying a corrected human factor IX gene), patients with hemophilia B experienced...
WIB_icon

Early-Phase Study Finds Duvelisib Active in Variety of Advanced Hematologic Malignancies

Thursday, February 1st, 2018
The oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib appeared to be active and tolerable at a range of doses and across a variety of...
WIB_icon

Brentuximab Vedotin Plus Nivolumab May Be an Alternative to Salvage Chemotherapy in Relapsed/Refractory Hodgkin...

Thursday, February 1st, 2018
In a phase I/II study published in Blood, the combination of brentuximab vedotin plus nivolumab was an effective first salvage therapy in patients with...
WIB_icon

Single-Agent Vadastuximab Talirine Active, Tolerable in AML

Thursday, February 1st, 2018
In a first-in-human study of patients with CD33-positive acute myeloid leukemia (AML), treatment with single-agent vadastuximab talirine (a CD33-targeted antibody-drug conjugate) resulted in a...

Nilotinib Receives Label Update on Information for Treatment Discontinuation

Thursday, February 1st, 2018
The FDA updated the product label for nilotinib to include information on treatment discontinuation for certain patients. Nilotinib is approved for the treatment of...

NDA Submitted for Ivosidenib for Relapsed/Refractory IDH1-Positive AML

Thursday, February 1st, 2018
The FDA received a new drug application (NDA) for ivosidenib (previously AG-120) for patients with relapsed/refractory IDH1-positive acute myeloid leukemia (AML). The NDA was based...

FDA Expands Approval for Bosutinib to Include Early-Phase CML

Thursday, February 1st, 2018
The oral tyrosine kinase inhibitor bosutinib received expanded approval from the U.S. Food and Drug Administration (FDA) to treat adults with newly diagnosed Philadelphia...

Poll: CVS, Aetna Merger Could Impact Health Benefits

Thursday, February 1st, 2018
In December 2017, CVS Health announced plans to purchase the health insurer Aetna for $69 billion, and according to a survey of decision-makers at...

February 2018 Issue

A Preview of ASH’s Venous Thromboembolism Clinical Practice Guidelines

Thursday, February 1st, 2018
In November 2015, the American Society of Hematology (ASH) and the McMaster University GRADE Center announced a collaboration to develop clinical practice guidelines on...

Newly Approved Drugs for AML: How to Use Them in Practice

Thursday, February 1st, 2018
In 2017, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of hematologic malignancies, including four for acute myeloid leukemia...

Preliminary Results Show Flotetuzumab Well-Tolerated and Effective in Relapsed/Refractory AML and MDS

Thursday, February 1st, 2018
In early results from a phase I trial presented at the 2017 ASH Annual Meeting, researchers reported that the bispecific antibody flotetuzumab demonstrated anti-leukemic...

Examining the Risk of Cardiovascular Disease–Related Mortality in Patients With and MDS/CMML

Thursday, February 1st, 2018
Patients with chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) have a higher risk of cardiovascular disease (CVD)–related mortality and cerebrovascular accident (CVA)–related mortality,...

Feeding the Fire: CHIP and Inflammation

Thursday, February 1st, 2018
Clonal hematopoiesis of indeterminate potential (CHIP), known as a “premalignant” state in the blood critical to the development of blood cancer, increases in frequency...

Treating MRD With Azacitidine in Patients With High-Risk AML and MDS

Thursday, February 1st, 2018
For 58 percent of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) at high risk for relapse, treatment of minimal residual disease...

Idasanutlin Well Tolerated in Patients With Polycythemia Vera and Essential Thrombocythemia

Thursday, February 1st, 2018
The MDM2 antagonist idasanutlin was well tolerated and demonstrated “clear clinical activity” in patients with polycythemia vera (PV) and essential thrombocythemia (ET) that was...

Haplo-HCT From Older Donors Associated With Worse Outcomes in Acute Leukemias

Thursday, February 1st, 2018
The use of haploidentical (haplo) related donors has made it possible for patients with leukemia who lack a human leukocyte antigen (HLA)–matched donor to...

Combining Recombinant Human Thrombopoietin With Corticosteroids in Immune Thrombocytopenia

Thursday, February 1st, 2018
Corticosteroids are the guideline-recommended firstline therapy for adult patients with immune thrombocytopenia (ITP), but a recent clinical trial suggests that regulating thrombopoiesis with recombinant...

Older Patients Underrepresented in Trials of Hematologic Malignancy Treatments

Thursday, February 1st, 2018
People over the age of 65 represent the majority of those diagnosed with hematologic malignancies, but they account for only about one-third of patients...

Social Media Quality Control for Physicians

Thursday, February 1st, 2018
Social media has infiltrated our everyday lives – both personally and professionally. With most people keeping in touch with friends, family, and colleagues and...

Shining a Spotlight on International Hematology Research and Initiatives

Thursday, February 1st, 2018
The 2017 ASH Annual Meeting marked the debut of the “Global Capacity-Building Showcase,” a new poster category for research and capacity-building initiatives in low-...

SHARE